Oxford Pharmascience Group

Oxford Pharmascience is a drug development company that re-develops approved drugs using proprietary formulation technologies to make them better, safer and easier to take. Since Oxford Pharmascience's products incorporate previously approved drugs, this reduces risk and results in a simplified drug development regulatory pathway allowing less expensive development programs and faster access to market. The Company's pipeline is focused on cardiovascular disease and pain relief indications addressing unmet patient needs with significant commercial potential in global markets. The company was founded in February'08 and floated in London's AIM market in February 2010.
Company Growth (employees)
London, GB
Size (employees)
10 (est)
Oxford Pharmascience Group was founded in 2008 and is headquartered in London, GB

Oxford Pharmascience Group Office Locations

Oxford Pharmascience Group has an office in London
London, GB (HQ)
2 Royal College Street, Camden
Show all (1)

Oxford Pharmascience Group Financials and Metrics

Oxford Pharmascience Group Financials

Oxford Pharmascience Group's revenue was reported to be £796 k in FY, 2016 which is a 6% increase from the previous period.

Revenue (FY, 2016)

796 k

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

200 k

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(1.4 m)

EBITDA (FY, 2016)

(2 m)

EBIT (FY, 2016)

(2 m)

Market capitalization (26-May-2015)

253.2 b

Closing share price (26-May-2015)


Cash (31-Dec-2016)

16.9 m
Oxford Pharmascience Group's current market capitalization is $253.2 b.
GBPFY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016


54 k123 k282 k466 k1 m705 k749 k796 k

Revenue growth, %


Cost of goods sold

32 k88 k249 k262 k693 k482 k591 k596 k

Gross profit

22 k35 k33 k204 k336 k223 k158 k200 k
GBPFY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016


638 k896 k1.1 m2.2 m9.9 m6.7 m13.1 m16.9 m

Accounts Receivable

13 k25 k115 k132 k108 k215 k179 k343 k


39 k104 k44 k42 k21 k20 k9 k14 k

Current Assets

846 k1.1 m1.3 m2.5 m10.2 m7.6 m24.1 m22.7 m
    GBPFY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    (229 k)(812 k)(926 k)(783 k)(1.5 m)(2.9 m)(3.1 m)(1.4 m)

    Cash From Operating Activities

    (354 k)(757 k)(863 k)(801 k)(1.2 m)(3.4 m)(3.2 m)(1.3 m)

    Cash From Financing Activities

    1.1 m1.1 m1.9 m8.9 m157 k19.4 m

    Net Change in Cash

    (351 k)258 k209 k1.1 m7.7 m(3.2 m)6.4 m3.8 m
      Y, 2016

      Financial Leverage

      1 x
      Show all financial metrics

      Oxford Pharmascience Group's Web-traffic and Trends

      Oxford Pharmascience Group Company Life and Culture

      You may also be interested in